Pharmacy benefit spending poised to increase for antithrombotic drug therapy - Prasugrel versus clopidogrel

Journal of Managed Care Pharmacy

Volumn 15, Issue 5, 2009, Pages 414-416

  Curtiss, Frederic R ^a   Fairman, Kathleen A ^b  

^a Academy of Managed Care Pharmacy   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; PRASUGREL; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACY; RECOMMENDED DRUG DOSE; ST SEGMENT ELEVATION; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; COMMERCIAL PHENOMENA; COMPARATIVE STUDY; ECONOMICS; HEALTH INSURANCE; NOTE; THROMBOSIS;

COMMERCE; DRUG COSTS; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES; THROMBOSIS; TICLOPIDINE;

EID: 67649990503     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.5.414     Document Type: Editorial

References (26)

1. Plavix 75 mg price for 30 tablets at www.drugstore.com. Accessed June 1, 2009.
2. Anonymous. SDI/Verispan, VONA. 2008 Top 200 branded drugs by retail dollars. Available at: http://drugtopics.modernmedicine.com/drugtopics/data/ articlestandard//drugtopics/192009/597083/article.pdf. Accessed June 1, 2009.
3. Anonymous. Top 200 brand drugs by retail dollars in 2007. Data from Verispan VONA. Drug Topics. March 10, 2008:28. Available at: http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard// drugtopics/102008/500221/article.pdf. Accessed June 1, 2009.
4. Anonymous. Top 200 brand drugs by retail dollars in 2002. Data from Verispan Scott-Levin SPA. Drug Topics. April 7, 2003:24.
5. U.S. Food and Drug Administration. Summary minutes of the Cardiovascular and Renal Drugs Advisory Committee. February 3, 2009. Available at: http://www.fda.gov/ohrms/dockets/ac/09/minutes/2009-4412m1-Final.pdf. Accessed June 1, 2009.
6. Alexander W. FDA advisory committee meeting on prasugrel for acute coronary syndromes. P&T. 2009;34(3):155-156
7. Prasugrel (LY640315; CS-747) as an anti-thrombotic therapy in patients with acute coronary syndromes (ACS). NDA 22-307 Effient (prasugrel). Presentation to the Cardiovascular and Renal Drugs Advisory Committee, February 3, 2009. Available at: http://www.fda.gov/ohrms/dockets/AC/09/slides/2009- 4412s1-02-sponsor.pdf. Accessed June 2, 2009.
8. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. Available at: http://content.nejm.org/cgi/reprint/357/20/2001.pdf. Accessed June 2, 2009. (Pubitemid 350106708)
9. Stone GW. Ischaemia versus bleeding: the art of clinical decision-making. Lancet. 2009;373(9665):695-696
10. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008;117(2):296-329. Available at: http://circ.ahajournals.org/cgi/reprint/117/ 2/296. Accessed June 2, 2009.
11. Schafer JA, Kjesbo NK, Gleason PP. Critical review of prasugrel for formulary decision makers. J Manag Care Pharm. 2009;15(4):335-343 Available at: http://www.amcp.org/data/jmcp/335-343.pdf.
12. U.S. Food and Drug Administration. Cardiovascular and Renal Drug Advisory Committee briefing document on prasugrel for ACS. February 3, 2009. Available at: http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-01-FDA.pdf. Accessed June 2, 2009.
13. Spinler SA, Rees C. Review of prasugrel for the secondary prevention of atherothrombosis. J Manag Care Pharm. 2009;15(5):383-395
14. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723-731
15. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626-1636
16. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371(9621):1353-1363
17. Johnson A, Rubenstein S. Lilly suspends two studies of key blood thinner drug. Wall Street J. Oct 25, 2007:A4. Available at: http://online.wsj.com/ article/SB119323938811069932.html?mod=googlewsj. Accessed June 2, 2009.
18. Favole JA. FDA says it erred on doctor. Wall Street J. Feb 24, 2009:D6. Available at: http://online.wsj.com/article/SB123544421394356087.html. Accessed June 2, 2009.
19. U.S. Food and Drug Administration. Plavix (clopidogrel). NDA no. 020-839/S-038. Label. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/label/2007/020839s0381bl.pdf. Accessed June 2, 2009.
20. Anderson T, Das I, Olson J, Sobelman D. Bristol-Myers Squibb: decent Q1; several pipeline-related events lie ahead. BernsteinResearch. April 29, 2009. Sanford C. Bernstein and Co., New York.
21. Anderson T, Das I, Olson J, Sobelman D. Sanofi-Aventis: strong Q1 results; pipeline rationalization continues (and doesn't seem to be done yet). BernsteinResearch. April 30, 2009. Sanford C. Bernstein and Co., New York.
22. Winslow R. Novartis acquires rights to heart drug. Wall Street J. February 12, 2009:B5. Available at: http://online.wsj.com/article/ SB123439562598774855.html. Accessed June 2, 2009.
23. Anderson T, Das I, Olson J, Sobelman D. Eli Lilly: prasugrel gets the go-ahead (as expected). BernsteinResearch. February 3, 2009. Sanford C. Bernstein and Co., New York.
24. Anonymous. A comparison of prasugrel and clopidogrel in acute coronary syndrome subjects (TRILOGY ACS). Registry of clinical trial # NCT00699998. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00699998?term= prasugrel&rank=5. Accessed June 2, 2009.
25. Choudhry NK, Levin R, Avorn J. The economic consequences of non-evidence-based clopidogrel use. Am Heart J. 2008;155(5):904-909
26. Jackson MA, Fairman KA, Curtiss FR. Prior authorization and clopiodgrel use: the truth lies in the details. J Manag Care Pharm. 2009;15(1):71-77. Available at: http://www.amcp.org/data/jmcp/071-077.pdf.